Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Bortezomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 16/20 | 0.98 |
| ▸ | PSMB8 known ✓ | P28062 | 8/20 | 0.98 |
| ▸ | PSMB9 known ✓ | P28065 | 8/20 | 0.98 |
| ▸ | PSMB6 known ✓ | P28072 | 8/20 | 0.98 |
| ▸ | PSMB10 known ✓ | P40306 | 8/20 | 0.98 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 7/20 | 0.98 |
| ▸ | PSMA7 known ✓ | O14818 | 7/20 | 0.98 |
| ▸ | PSMB1 known ✓ | P20618 | 7/20 | 0.98 |
| ▸ | PSMA1 known ✓ | P25786 | 7/20 | 0.98 |
| ▸ | PSMA2 known ✓ | P25787 | 7/20 | 0.98 |
| ▸ | PSMA3 known ✓ | P25788 | 7/20 | 0.98 |
| ▸ | PSMA4 known ✓ | P25789 | 7/20 | 0.98 |
| ▸ | PSMA5 known ✓ | P28066 | 7/20 | 0.98 |
| ▸ | PSMB4 known ✓ | P28070 | 7/20 | 0.98 |
| ▸ | PSMB3 known ✓ | P49720 | 7/20 | 0.98 |
| ▸ | PSMB2 known ✓ | P49721 | 7/20 | 0.98 |
| ▸ | PSMA6 known ✓ | P60900 | 7/20 | 0.98 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 7/20 | 0.98 |
| ▸ | PSMB7 known ✓ | Q99436 | 7/20 | 0.98 |
| ▸ | PSMD11 known ✓ | O00231 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bortezomib SCHEMBL15720950 | 1.00 | PSMB5 (0.98) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL17075364 | 1.00 | PSMB5 (0.98) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL192129 | 0.99 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8099424 | 0.99 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL29377226 | 0.99 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL3676 | 0.99 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8035134 | 0.99 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL466239 | 0.99 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8049740 | 0.99 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL30316729 | 0.99 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9217001-B2 | Crystalline bortezomib process | SHILPA MEDICARE LIMITED (IN) | 2015-12-22 | — | — | US | disclosed |
| US-20150259364-A1 | CRYSTALLINE BORTEZOMIB PROCESS | SHILPA MEDICARE LIMITED (IN) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259364-A1 | CRYSTALLINE BORTEZOMIB PROCESS | BBC3, PSMB2, PSMA2 | PSMB5 7/4885PSMB8 26/4885PSMB9 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.